To give an overview of the pharmaceutical industries' current challenges and their implications.
This briefing is prepared by an independent writer who adds their own impartial comments.
Despite the fact we're all getting older, our expectations of an ever longer, healthier and pain‐free life seem to grow by the day. Advertising everywhere boasts of the latest so‐called “wonder drug”, youth is increasingly being preserved and we are encouraged by pharmaceutical CE David Brennan to understand that “Death is optional”. The pharmaceutical industry is thus one of the supposed lucky ones: the demand for drugs and medicines can and will only go up. So it would be easy to think that shares in the biggest players in the field would offer a decent long term investment. Easy to think perhaps; also perhaps a big mistake.
Offers strategic, political and financial insights into the current climate of the pharmaceutical sector.
Covers the most pressing concerns faced by the big drug companies and considers the impact of these issues on shareholders, drug users and the organizations involved.
